Mammotome, the new name for the former the breast-care business of Johnson & Johnson‘s Ethicon Endo-Surgery, has hired a number of senior executives as the company rounds out its leadership team.
The company sells the Mammotome Breast Biopsy System, and several tissue markers used for diagnostic sampling and management of potentially diseased breast tissue in 50 countries. Mammotome was the first acquisition for Devicor Medical Products, a Wisconsin-based medical device holding company that was set up two years ago with a $250 million investment from Chicago private equity firm GTCR Golder Rauner LLC.
Devicor has strong ties to Cardinal Health (NYSE:CAH). Its top two executives, CEO Thomas Daulton and executive vice president, Jonathan Salkin, are both former Cardinal employees, as are several other executives.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Those joining Daulton and Salkin on Mammotome’s senior leadership team include: Joe Trentacosta, chief financial officer; Mark Ehlert, senior vice president of scientific affairs; Kent Rex, chief operating officer; and Kevin Cleary, senior vice president of global sales, according to a statement from the company.
Devicor purchased the Ethicon Endo-Surgery unit, now Mammotome, in July for an undisclosed price.
